Alzinova Investor Relations Material
Latest events
Study Result
Alzinova
Q1 2025
15 May, 2025
Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Alzinova
Access all reports
Alzinova AB is a Swedish biotechnology company focused on developing treatments for Alzheimer's disease. The company's lead product is ALZ-101, a vaccine designed to target toxic oligomers of amyloid-beta, which are implicated in the progression of Alzheimer's. ALZ-101 has completed part A of its phase 1b clinical trial and continues to progress through clinical development. Alzinova is also working on ALZ-201, a monoclonal antibody that neutralizes these toxic oligomers, with a humanized version in early clinical trials. The company is headquartered in Mölndal, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
ALZ
Country
🇸🇪 Sweden